Evaluating only Nabriva Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
Founded in Vienna, Austria, spun out of Sandoz to develop next-generation pleuromutilin antibiotics.
PRODUCT LAUNCH
FDA approved Xenleta (lefamulin) for community-acquired bacterial pneumonia — first new antibiotic class in 20 years.
SHUTDOWN
Nabriva halted US commercialization of Xenleta after quarterly revenues peaked at only $2.8M vs $30M+ expenses.
SHUTDOWN
Nabriva Therapeutics fully dissolved, unable to find acquirer for Xenleta despite FDA-approved status.
Full Analysis
Free · no account needed
Documented cause
Nabriva received FDA approval for lefamulin (Xenleta) in August 2019 for community-acquired bacterial pneumonia, but commercial sales were catastrophically low. Peak quarterly revenue never exceeded $3M against operating expenses of $30M+. The antibiotic market's structural pricing and reimbursement problems made profitability impossible. Nabriva halted US commercialization in October 2021 and fully dissolved in 2023.
Lesson
“Market approval means nothing without viable reimbursement pathways — antibiotics are a broken commercial model.”